Contact
searchSearch
HMP Global
Login

Cholangiocarcinoma Resource Center

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways
News
Translating Hypertension Guidelines Into Scalable Care Pathways
03/16/2026
Hannah Musick
Clarifying the distinct roles of clinical practice guidelines, treatment protocols, and care pathways may help health systems translate hypertension evidence into standardized primary care programs that improve blood pressure control and...
Clarifying the distinct roles of clinical practice guidelines, treatment protocols, and care pathways may help health systems translate hypertension evidence into standardized primary care programs that improve blood pressure control and...
Clarifying the distinct roles of...
03/16/2026
Journal of Clinical Pathways
News
Geographic Barriers Limit CAR T-Cell Therapy Access in US Medicare Patients With DLBCL
03/12/2026
Grace Taylor, MS, MA
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in...
03/12/2026
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
News
Social Drivers Linked to Hepatocellular Carcinoma Stage and Survival in US Integrated Care System
03/09/2026
Hannah Musick
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health...
03/09/2026
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab Plus Paclitaxel for Platinum-Resistant Ovarian Cancer in the US
03/06/2026
Hannah Musick
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug...
03/06/2026
Journal of Clinical Pathways
News
Real-World Data Support Earlier T-DXd Use in HR+/HER2-Low Metastatic Breast Cancer
03/04/2026
Grace Taylor, MS, MA
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab...
03/04/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Quality Outlook
The Rising and Setting of Health Equity
02/24/2026
David Sloan, PhD; Tom Valuck, MD, JD
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating...
02/24/2026
Journal of Clinical Pathways
eNews Sign-up

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use